Sanofi Forces Genzyme's Hand With Hostile Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
With no white knight in Genzyme's corner, Sanofi commences a tender offer for Genzyme at $69-per-share.
You may also be interested in...
No Means No: Genzyme Responds To Sanofi's Hostile Bid
Sanofi CEO Viehbacher indicated a price of $69- to $80-per-share would be acceptable, Genzyme reveals in an SEC filing.
No Means No: Genzyme Responds To Sanofi's Hostile Bid
Sanofi CEO Viehbacher indicated a price of $69- to $80-per-share would be acceptable, Genzyme reveals in an SEC filing.
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards